Buscar resultados de ensayos clínicos
Encephalomyelitis - 25 Studies Found
Estado | Estudiar |
Completed |
Nombre del estudio: Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone Condición:
Intervenciones: Procedure: Plasma exchange |
Active, not recruiting |
Nombre del estudio: Biobank For MS And Other Demyelinating Diseases Condición:
|
Enrolling by invitation |
Nombre del estudio: Safety and Immunogenicity Study of the Venezuelan Equine Encephalomyelitis Vaccine Condición: Venezuelan Equine Encephalomyelitis Fecha: 2007-12-19 Intervenciones: Biological: VEE TC-83 Subjects will receive a single 0.5 mL dose by subcutaneous route in the upper oute |
Recruiting |
Nombre del estudio: Oral Melatonin Plus Zinc Supplementation in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) Condición:
Fecha: 2016-12-19 Intervenciones:
|
Completed |
Nombre del estudio: The Study of the Safety and Efficacy of Ampligen in Chronic Fatigue Syndrome Condición:
Fecha: 2005-09-16 Intervenciones: Drug: Ampligen |
Terminated |
Nombre del estudio: Tumor Necrosis Factor-alpha Inhibition Using Etanercept in Chronic Fatigue Syndrome Condición:
Fecha: 2012-11-08 Intervenciones: Drug: Etanercept Weekly subcutaneous injections of Etanercept 50 mg, for up to 12 months. |
Recruiting |
Nombre del estudio: Reducing Orthostatic Intolerance With Oral Rehydration in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients Condición:
Intervenciones: |
Recruiting |
Nombre del estudio: Myalgic Encephalomyelitis Chronic Fatigue at the National Institutes of Health Condición: Chronic Fatigue Syndrome Fecha: 2016-01-29 |
Terminated |
Nombre del estudio: B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Very Severe Chronic Fatigue Syndrome Condición:
Fecha: 2010-07-02 Intervenciones: Drug: Rituximab Two infusions of Rituximab 500 mg/m2 (max |
Completed |
Nombre del estudio: B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome Condición:
Fecha: 2010-07-02 Intervenciones: Drug: Rituximab Two infusions of Rituximab 500 mg/m2 (max |